Treatment guidelines for onychomychosis
Reading Document
Medical Text Search
onychomycosis treatment guidelines antifungal therapy
Medical Text Search
onychomycosis diagnosis classification topical oral antifungal
GradeResponse
GradeResponse
Here is a comprehensive overview of onychomycosis treatment guidelines, combining retrieved sources with established clinical knowledge.
Onychomycosis: Treatment Guidelines
Overview
Onychomycosis is a fungal infection of the nail unit, accounting for ~50% of all nail disorders. It is caused predominantly by dermatophytes (Trichophyton rubrum, T. mentagrophytes), less commonly by non-dermatophyte molds and Candida spp. Treatment decisions must weigh extent of disease, causative organism, patient comorbidities, and drug interactions against the cost and adverse effect profile of antifungals.
Key principle (Harrison's, p. 6316): Treating for cosmetic reasons alone is discouraged. The extent of nail involvement must justify systemic therapy given its adverse effects, drug interactions, and cost.
Classification (OSI / Scoring Systems)
| Type | Features |
|---|---|
| Distal Lateral Subungual Onychomycosis (DLSO) | Most common; invasion from hyponychium |
| Superficial White Onychomycosis (SWO) | Nail plate surface; T. mentagrophytes or molds |
| Proximal Subungual Onychomycosis (PSO) | Proximal nail fold; common in immunocompromised |
| Total Dystrophic Onychomycosis (TDO) | Complete nail destruction; end-stage |
| Endonyx Onychomycosis | Diffuse nail plate invasion without subungual hyperkeratosis |
The Onychomycosis Severity Index (OSI) and Scoring Clinical Index for Onychomycosis (SCIO) help guide treatment intensity.
Diagnosis Before Treatment
Confirm fungal etiology before initiating therapy:
- KOH preparation (quick, low cost, ~60–80% sensitivity)
- Fungal culture (gold standard for speciation, 3–6 weeks)
- PAS histology of nail clippings (highest sensitivity ~80–90%)
- PCR-based testing (rapid, high sensitivity, identifies species)
Do not treat empirically without confirmation — differential includes psoriasis, lichen planus, trauma, and pachyonychia.
Treatment Algorithm
Step 1: Assess Candidacy for Treatment
- Confirm diagnosis mycologically
- Assess nail involvement (% area, number of nails, matrix involvement)
- Evaluate contraindications to systemic therapy (liver disease, drug interactions, pregnancy)
Step 2: Choose Modality Based on Severity
| Severity | Preferred Approach |
|---|---|
| Mild–Moderate (< 50% nail, no matrix) | Topical antifungal (monotherapy or adjunct) |
| Moderate–Severe (> 50% nail or matrix involved) | Systemic oral antifungal |
| Refractory / Total Dystrophic | Combination oral + topical ± nail avulsion |
Topical Antifungals
Suitable for mild, superficial, or distal disease without matrix involvement.
| Agent | Formulation | Regimen | Notes |
|---|---|---|---|
| Efinaconazole 10% (Jublia) | Solution | Daily × 48 weeks (toenail) | FDA-approved; good nail penetration |
| Tavaborole 5% (Kerydin) | Solution | Daily × 48 weeks (toenail) | Boron-based; FDA-approved |
| Ciclopirox 8% (Penlac) | Nail lacquer | Daily × 12 months | Older agent; lower cure rates (~6–9%) |
| Amorolfine 5% | Nail lacquer | 1–2×/week | Available in Europe; not FDA-approved in US |
- Mycologic cure with topical monotherapy: ~15–55% depending on agent and disease extent
- Best results in SWO and mild DLSO
Systemic (Oral) Antifungals
Preferred for moderate-to-severe disease, matrix involvement, or multiple nails.
| Agent | Dose | Duration | Cure Rate | Key Concerns |
|---|---|---|---|---|
| Terbinafine | 250 mg/day | 6 wks (fingernail), 12 wks (toenail) | ~70–80% mycologic | Hepatotoxicity (rare); check LFTs if risk factors |
| Itraconazole (continuous) | 200 mg/day | 6 wks (fingernail), 12 wks (toenail) | ~60–70% mycologic | CYP3A4 inhibitor; negative inotrope; many interactions |
| Itraconazole (pulse) | 200 mg BID × 1 wk/month | 2 pulses (fingernail), 3 pulses (toenail) | ~60% mycologic | Reduces total drug exposure |
| Fluconazole | 150–300 mg once weekly | 3–6 months (fingernail), 6–12 months (toenail) | ~50–60% mycologic | CYP2C9/3A4 inhibitor; off-label for onychomycosis |
Terbinafine is the preferred first-line agent for dermatophyte onychomycosis due to superior mycologic and clinical cure rates.
Itraconazole is preferred for Candida and non-dermatophyte mold infections.
Combination Therapy
Oral + topical combination (e.g., terbinafine + efinaconazole) improves complete cure rates and reduces relapse, particularly in severe or recalcitrant cases.
Adjunctive Measures
- Nail debridement/avulsion: Chemical (40% urea) or mechanical; reduces fungal load; improves topical penetration
- Laser therapy (Nd:YAG, CO₂): Emerging; may improve cure rates as adjunct; not yet a standard of care
- Photodynamic therapy (PDT): Investigational
Special Populations
| Population | Considerations |
|---|---|
| Immunocompromised (HIV, transplant) | Higher risk of PSO; longer treatment; may need IV antifungals |
| Diabetes | Treat aggressively; risk of secondary bacterial infection |
| Elderly | Polypharmacy risk; renal dosing adjustments |
| Pregnancy | Avoid systemic azoles and terbinafine; topical only (ciclopirox preferred) |
| Children | Terbinafine weight-based dosing; itraconazole off-label |
Monitoring
- Terbinafine: Baseline LFTs; repeat if symptoms develop or treatment > 6 weeks in at-risk patients
- Itraconazole: Baseline LFTs; avoid in heart failure; monitor drug interactions
- Response assessment: Clinical and mycologic cure assessed at 3–6 months after treatment completion (nails grow slowly)
Relapse & Recurrence
Relapse occurs in 25–30% of cases following treatment (Harrison's, p. 6316). Risk factors include:
- Tinea pedis (treat concurrently)
- Immunosuppression
- Peripheral vascular disease
- Genetic susceptibility
Preventive measures: Antifungal foot powder, breathable footwear, treatment of concurrent tinea pedis, nail hygiene.
Summary
- Confirm diagnosis mycologically before treating
- Terbinafine 250 mg/day × 12 weeks is first-line for toenail dermatophyte onychomycosis
- Use topical agents (efinaconazole, tavaborole) for mild/distal disease or as adjuncts
- Treat tinea pedis concurrently to reduce relapse
- Cosmesis alone is not an indication for systemic therapy
This is a shared conversation. Sign in to Orris to start your own chat.